Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. McDermott DF, et al. Among authors: rathmell wk. Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z. Nat Med. 2018. PMID: 30291359
Renal cell carcinoma.
Rathmell WK, Godley PA, Rini BI. Rathmell WK, et al. Curr Opin Oncol. 2005 May;17(3):261-7. doi: 10.1097/01.cco.0000155007.51495.d6. Curr Opin Oncol. 2005. PMID: 15818172 Review.
Molecularly targeted therapy in renal cell carcinoma.
Rathmell WK, Wright TM, Rini BI. Rathmell WK, et al. Expert Rev Anticancer Ther. 2005 Dec;5(6):1031-40. doi: 10.1586/14737140.5.6.1031. Expert Rev Anticancer Ther. 2005. PMID: 16336094 Review.
Renal cell carcinoma.
Rini BI, Campbell SC, Rathmell WK. Rini BI, et al. Among authors: rathmell wk. Curr Opin Oncol. 2006 May;18(3):289-96. doi: 10.1097/01.cco.0000219260.60714.c4. Curr Opin Oncol. 2006. PMID: 16552243 Review.
Renal cell carcinoma.
Rathmell WK, Martz CA, Rini BI. Rathmell WK, et al. Curr Opin Oncol. 2007 May;19(3):234-40. doi: 10.1097/CCO.0b013e3280ad4388. Curr Opin Oncol. 2007. PMID: 17414642 Review.
Renal cell carcinoma.
Rini BI, Rathmell WK, Godley P. Rini BI, et al. Among authors: rathmell wk. Curr Opin Oncol. 2008 May;20(3):300-6. doi: 10.1097/CCO.0b013e3282f9782b. Curr Opin Oncol. 2008. PMID: 18391630 Review.
State of the science: an update on renal cell carcinoma.
Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. Jonasch E, et al. Among authors: rathmell wk. Mol Cancer Res. 2012 Jul;10(7):859-80. doi: 10.1158/1541-7786.MCR-12-0117. Epub 2012 May 25. Mol Cancer Res. 2012. PMID: 22638109 Free PMC article. Review.
ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma.
Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK. Brooks SA, et al. Among authors: rathmell wk. Eur Urol. 2014 Jul;66(1):77-84. doi: 10.1016/j.eururo.2014.02.035. Epub 2014 Feb 25. Eur Urol. 2014. PMID: 24613583 Free PMC article.
306 results